EVRISIRAN
UNII LDT7DM6RMG

Substance Identification & Data

This profile provides standardized clinical and technical data for Evrisiran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LDT7DM6RMG.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3110420-82-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

LDT7DM6RMG

CAS Registry Number

3110420-82-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

EVRISIRAN

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

13834

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Evrisiran

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Evrisiran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Evrisiran

Common Names & Synonyms

O-[(2R,3S)-2-(hydroxymethyl)oxolan-3-yl] hydrogen all-P-ambo-5'-O-({[(2R,3S)-3-{[{[1-(1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-9,13-bis{2-[(2-{2-[(2-acetamido-2-deoxy-β-Dgalactopyranosyl) oxy]ethoxy}ethyl)amino]-2-oxoethyl}-7,14-dioxo-3-oxa-6,9,13-triazaoctadecan-18-oyl)piperidin-4-yl]oxy}(sulfanyl)phosphoryl]oxy}oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-Omethyluridylyl-( 3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-Omethylcytidylyl-( 3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-Omethyluridylyl-( 3'→5')-2'-O-methyluridylyl-(3'→5')-2'-Omethyladenylyl-( 3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thio-3'-adenylate, duplex with all-P-ambo-2'-O-methyl-P-thioadenylyl-(5'→3')-2'-Omethyl-P-thiocytidylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-Omethyluridylyl-( 5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoradenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-Omethyluridylyl-( 5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-Omethyladenylyl-( 5'→3')-2'-O-methyl-P-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-(Rp)-P-thioguanylyl-(5'→3')-2'-O-methyluridine

RNA, ([1′-de(6-amino-9H-purin-9-yl)]A-(5′→5′)-sp-Um-Gm-Um-Cm-Am-Gm-Um-Um-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)A-Cm-Um-Um-Am-Um-Um-Cm-sp-Am-(3′→3′)-sp-[1′-de(6-amino-9H-purin-9-yl)]A), 3′-[O-[1-[18-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-6,10-bis[2-[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]-2-oxoethyl]-1,5,12-trioxo-16-oxa-6,10,13-triazaoctadec-1-yl]-4-piperidinyl] hydrogen phosphorothioate], complex with RNA (Um-[P(R)]-sp-(2′-deoxy-2′-fluoro)G-sp-Am-Am-Um-Am-(2′-deoxy-2′-fluoro)A-Gm-Um-Gm-Am-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)C-Um-Gm-Am-sp-Cm-sp-Am) (1:1)

evrisiran [INN]

External Clinical & Regulatory Resources

Previous UNIILDT5VM3SIQ

Next UNIILDU4EA3ZM8